Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...

BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded ...

The segment spotlighted the Baylor-led research recently published in Nature Medicine evaluating autologous Multi-Antigen Targeted T cell therapy in patients with pancreatic ductal adenocarcinoma ...

Certain of AIM’s leadership have indicated to the Company on a non-binding basis that they intend to participate in the Rights Offering, including Board member and Chief Executive Officer Thomas K.

HONG KONG SAR - Media OutReach Newswire - 26 January 2026 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today the initiation of a Phase I clinical study ...

Immunotherapy innovation is saving the lives of cancer patients across the country, while researchers continue to break new ground in this growing oncology field. When Sameek Roychowdhury, MD, PhD, ...

The aggressive brain cancer glioblastoma is infamously “cold” when it comes to immunotherapy, meaning it typically doesn’t respond to immune-boosting therapies because of immune-suppressing molecules ...

If you’ve ever conducted experiments with compounds targeting tumor cells, you likely understand the disappointment of promising results in cell cultures not translating to success in live animal ...

A sensor identifies misfolded protein biomarkers in the blood. This offers a chance to detect Alzheimer's disease before any symptoms occur. Researchers intend to bring it to market maturity. The ...

There's mounting research to suggest that protecting people who are immuno-compromised from getting COVID is important not just for their sake – it could be critical in the effort to end the pandemic ...